Business Wire

ADANI-ENTERPRISES

2.6.2024 18:10:35 CEST | Business Wire | Press release

Share
Stronger Than Ever: Adani Portfolio Delivers Record Performance

In line with their commitment to upholding the highest standards of transparency, below is the Adani Portfolio’s Credit and Result compendium for financial year 2023-24.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602830505/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Consistently improving financial performance (in INR crore) - in charts (Graphic: Business Wire)

The performance in FY24 and the past five years signify the strength and stability of the Adani Portfolio and the robustness of its businesses, which despite all external volatilities and headwinds, continue to deliver strong and consistent growth. It also highlights the superior capital allocation strategy that maximises returns and minimises risks.

Adani Portfolio reports strongest financial results till date

In FY24, the Adani Portfolio of companies rose to its best, showcasing resilience, strength and stability and delivering a record EBITDA growth of 45%. With surging cashflows and enhanced credit profiles, the Adani Portfolio is in a ‘stronger than ever’ position to accelerate growth.

  • EBITDA: Consistently advancing EBITDA increased to USD 10 Bn with record 45% growth year-on-year, highest in the history of the Adani Portfolio.
  • Cash Profit or FFO: Cash Profit of Funds Flow from Operations (FFO) was at USD 6.7 Bn, registering a growth of 51% year-on-year, thanks to its disciplined investment strategy providing high conversion of EBITDA into cash profit.
  • Core infrastructure EBITDA: The core infra and utility platform generated USD 8.3 Bn or 84% of the total EBITDA. The user base of the platform increased to over 350 million, with a fast-growing consumer franchise across airports, electricity distribution, smart metering, gas distribution and direct to consumer digital platform.
  • Gross Assets: Total Gross Assets increased by USD 8 Bn or 16% and now stand at USD 57.4 billion.
  • Conservative leveraging: Rising cash profit lowered the net leverage significantly. Net Debt to EBITDA is down from 3.3x at the end of FY23 to 2.2x, notably lower than the industry benchmark.
  • Liquidity position: Cash reserves of USD 7.2 Bn at the portfolio level was the highest ever, up 48.5% from last year and was at 24.8% of gross debt.
  • Ratings: Predictable cashflows led to multiple rating upgrades across portfolio companies. Adani Ports and Special Economic Zone became the first largescale Indian infrastructure company to be rated ‘AAA’. Now, three listed portfolio companies — APSEZ, Ambuja Cement and ACC — have the highest INR rating of ‘AAA’. There are two ‘AAA’ rated entities under AESL, namely Alipurduar Transmission and Western Transmission.
  • Diversified funding sources: The Adani Portfolio debt profile represents a balanced exposure to domestic banking, global banking and capital markets. Of the total debt mix, domestic banking exposure stands at 36% and domestic capital markets at 5% whereas 26% is the exposure to the global banking market; the global capital market is at 29% and the balance 4% is with others.

For compendiums download:

https://www.adani.com/-/media/Project/Adani/Invetsors/Q4%20FY24%20Performance

About The Adani Portfolio of Companies

Headquartered in Ahmedabad, the Adani portfolio is the largest and fastest-growing portfolio of diversified businesses in India with interests in logistics (seaports, airports, shipping and rail), resources, power generation and distribution, renewable energy, gas and infrastructure, agro (commodities, edible oil, food products, cold storage and grain silos), public transport infrastructure, defence, and other sectors. Adani owes its success and leadership position to its core philosophy of ‘Nation Building’ and ‘Growth with Goodness’, a guiding principle for sustainable growth. The Portfolio is committed to protecting the environment and improving communities through its CSR programmes based on the principles of sustainability, diversity, and shared values.

Further information at www.adani.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240602830505/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye